NCT06992258View on ClinicalTrials.gov

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions

Colorectal Cancer

Interventions

DRUG

Fruquintinib+ Lonsurf (trifluridine and tipiracil)

Experimental arm

DRUG

Fruquintinib

Standard Of Care Arm

Sponsors

Lead Sponsor

Criterium, Inc.

All Listed Sponsors

lead

Criterium, Inc.

INDUSTRY